Day One
Program
Day 1: Monday, October 23, 2017
Session A – HIV "Cure" Research
Despite long-term control of HIV replication with combination antiretrovirals, HIV persists as silenced integrated DNA in memory CD4 T cells, and possibly in other cellular reservoirs, including naïve cells and macrophages. Low-level replenishment of the reservoir via limited cycles of replication may also contribute to persistence, at least in some patients. Curing HIV infection will only occur if these barriers are reversed, or if host capacity to control HIV indefinitely is improved. The observation that few patients treated during primary infection durably control replication-competent HIV after interrupting therapy suggests host responses might be manipulated, leading to a functional cure. To tackle these issues, this session provides an opportunity for scientists to share ideas and debate in order to accelerate research on viral reservoirs and latency as the way towards achieving a cure for HIV infection.
Chairpersons and Discussants:
Diana Finzi, PhD, National Institutes of Health
Robert Siliciano, MD, Johns Hopkins University
Carl Dieffenbach, PhD, DAIDS
Schedule:
8:30 AM
Presentation Title: Immune Checkpoint Blockade
Speaker: Monsef Benkirane, PhD, University of Montpellier
8:55 AM
Presentation Title: Antibody binding to HIV-1 infected cells as mechanism for treatment of HIV infection
Speaker: Guido Ferrari, MD, Duke University
9:20 AM
Presentation Title: Combined immune-based strategies targeting viral persistence in ART-suppressed SIV-infected rhesus macaques
Speaker: Mirko Paiardini, PhD, Emory University
9:45 AM
Presentation Title: Immune Targeting of the Latent Reservoir
Speaker: Douglas Nixon, MD, PhD, George Washington University
Coffee Break, 10:10 AM - 10:25 AM
10:25 AM
Presentation Title: No evidence for HIV replication in lymph nodes during ART
Speaker: Mary Kearney, PhD, National Cancer Institute
10:50 AM
Presentation Title: Eradication of HIV; molecular therapeutic paths to a functional cure
Speaker: Kevin Morris, PhD, Beckman Research Institute of the City of Hope
11:15 AM
Presentation Title: Early ART and HIV Remission: Experience from the RV254 and related HIV remission studies
Speaker: Jintanat Ananworanich, MD, PhD, U.S. Military HIV Research Program
11:40 AM
Presentation Title: The contribution of memory CD4+ T cell subset phenotype to latency reversal efficiency
Speaker: Deanna Kulpa, PhD, Emory University
12:05 AM
Presentation Title: Cytotoxic T lymphocytes shape the landscape of HIV-1 proviruses
Early-stage Speaker: Ya-Chi Ho, MD, PhD, Johns Hopkins University
Lunch, 12:25 PM – 1:35 PM
Session B – Emerging Concepts in Cancer Therapy
Immuno-oncology research and the subsequent development of immunotherapies continue to rapidly advance the fight against cancer. First-generation agents achieving remarkable clinical success have inspired researchers to pursue a variety of new treatment modalities, creating a robust development landscape now centered on combinations strategies. These next-generation agents, in combination with targeted therapies or other immune-modulators such as checkpoint antibodies, are poised to significantly enhance clinical response in a wider range of cancers.
Chairpersons and Discussants:
Eduardo Sotomayor, MD, George Washington University
Isaac Witz, PhD, Tel Aviv University
Schedule:
1:35 PM
Presentation Title: Shooting many birds (cytokines) with a single stone - introduction to a new therapeutic strategy
Speaker: Yutaka Tagaya, PhD, Institute of Human Virology
1:55 PM
Presentation Title: Results from a First-In-Human Study with BNZ-1, a Novel, Selective Inhibitor of IL-2, IL-9, and IL-15 at the Common Gamma-Chain Receptor, in Clinical Development for the Treatment of HAM/TSP and T-Cell Malignancies
Speaker: Paul Frohna, MD, PhD, PharmD, Bioniz Therapeutics
2:05 PM
Presentation Title: Fc Bridged Cellular Cytotoxicity (FcBCC): a novel mechanism by which NK cells recognize HSV
Speaker: Michael Caligiuri, MD, Ohio State University
2:25 PM
Presentation Title: Cancer Vaccine: Tumor Immunology meets....Immunology
Speaker: Roberto Accolla, MD, PhD, University of Insubria
2:50 PM
Presentation Title: Discovery to first-in-man studies of a multi-peptide-based hepatocellular carcinoma vaccine - HEPAVAC
Speaker: Luigi Buonaguro, MD, National Cancer Institute Fondazione Pascale
3:15 PM
Presentation Title: Cell-based Immunotherapy for Human Cancer
Early-stage Speaker: Hua Cheng, PhD, Institute of Human Virology
Coffee Break, 3:40 PM - 3:55 PM
Session C – Preventative and Therapeutic Vaccines
Progress in achieving an effective HIV vaccine has been thwarted by the high variability of the virus and inability to achieve sustainable immune responses to key viral antigens. Of particular interest is the application of new technologies to create more stable structures that will block viral entry and to optimize broadly neutralizing antibodies. In addition, this session includes current updates on therapeutic vaccines for HIV and other viral infections.
Chairpersons and Discussants:
Gunnel Biberfeld, MD, Karolinska Institute
George Lewis, PhD, Institute of Human Virology
Schedule:
3:55 PM
Presentation Title: Production and properties of SOSIP trimers
Speaker: John Moore, PhD, Cornell University
4:20 PM
Presentation Title: Long-term delivery of antiviral monoclonal antibodies
Speaker: Ronald Desrosiers, PhD, University of Miami
4:45 PM
Presentation Title: Germline-targeting vaccine design for HIV
Speaker: William Schief, PhD, Scripps Research Institute Vaccine Design
5:10 PM
Presentation Title: Defining the glycopeptide epitopes of broadly neutralizing antibodies
for HIV vaccine design
Speaker: Lai-Xi Wang, PhD, University of Maryland College Park
5:35 PM
Presentation Title: Quaternary Configuration of the HIV-1 Receptor-Binding Site
Speaker: Paolo Lusso, MD, PhD, National Institute of Allergy and Infectious Diseases
6:00 PM
Presentation Title: Pan-neutralizing antibodies derived from human plasma targeting a new epitope
Early-stage Speaker: Mohammad Sajadi, MD, Institute of Human Virology